#alzheimer039s — Public Fediverse posts

A team of researchers in Japan has found that a cognitive decline from a continued habit of eating high-calorie food is due to abnormalities in the synapses, junctions between nerve cells. https://www.japantimes.co.jp/news/2026/10/15/japan/science-health/high-calorie-diet-brain-abnormalities/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #health #food #obesity #brain #aging #alzheimer039s

Clinical trials for the treatment of Alzheimer's disease continue to face a global shortage of participants despite the arrival of new drugs and treatments, a trend that could slow progress in dementia therapies. https://www.japantimes.co.jp/news/2026/09/21/japan/science-health/alzheimers-day/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #aging #elderly #mentalhealth #alzheimer039s #medicine #pharmaceuticals #dementia #lecanemab #donanemab

South Korea is aging faster than any other nation, and lacking enough doctors, social workers or family caregivers to support its older adults, artificial intelligence is helping fill some of that gap. https://www.japantimes.co.jp/news/2026/04/30/asia-pacific/society/south-korea-ai-elderly/?utm_medium=Social&utm_source=mastodon #asiapacific #society #southkorea #ai #elderly #aging #nursingcare #dementia #alzheimer039s #retirement

Mary Beth Hurt Dies: ‘The Age of Innocence’ & ‘Six Degrees of Separation’ Actress Was 79
#News #Obituaries #Alzheimer039s #MaryBethHurt #PaulSchrader

https://deadline.com/2026/03/mary-beth-hurt-dies-79-1236768661/

More than 90% of patients receiving Alzheimer's drug Lecanemab in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers has said. https://www.japantimes.co.jp/news/2026/03/25/japan/science-health/alzheimers-drug-lecanemab-safety/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #drugs #health

Chris Hemsworth Was Worried Fans Would “No Longer Believe” Him As Leading Man After Revealing Alzheimers Genetic Predisposition
#News #Alzheimer039s #ChrisHemsworth #ChrisHemsworthARoadTriptoRemember #Health

https://deadline.com/2026/02/chris-hemsworth-worried-believe-leading-man-alzheimers-1236710882/

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways. https://www.japantimes.co.jp/news/2025/12/12/world/science-health/alzheimers-trials-shift-approach/?utm_medium=Social&utm_source=mastodon #worldnews #sciencehealth #aging #dementia #alzheimer039s #pharmaceuticals #medicine #eisai #novonordisk

Scientists are still asking if GLP-1 drugs should be tested to prevent Alzheimer's in people at risk. https://www.japantimes.co.jp/business/2025/11/26/companies/novo-nordisk-glp-1-alzheimers/?utm_medium=Social&utm_source=mastodon #business #companies #novonordisk #alzheimer039s #pharmaceuticals

In fast-aging Japan, struggles with dementia are a common story. But researchers hope that future breakthroughs will help them rewrite the ending. https://www.japantimes.co.jp/news/2025/09/17/japan/science-health/dementia-research/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #aging #elderly #mentalhealth #alzheimer039s #medicine #pharmaceuticals #dementia #lecanemab #donanemab

A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals #eisai #health

Japan is expected to lower the price of lecanemab, an Alzheimer's drug, following a health ministry panel's report citing its low cost-effectiveness. https://www.japantimes.co.jp/news/2025/07/10/japan/science-health/lecanemab-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #lecanemab #alzheimer039s #medicine #health #dementia

A Japanese research team has started a final-stage clinical trial to treat familial Alzheimer's disease patients with a drug discovered through induced pluripotent stem (IPS) cells. https://www.japantimes.co.jp/news/2025/06/04/japan/science-health/alzheimers-ips-drug-trial/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #ips

The loss of a certain immune-regulating protein in the brain leads to a decrease in the levels of amyloid beta, which causes Alzheimer's disease, researchers including from Kyoto University found. https://www.japantimes.co.jp/news/2025/05/08/japan/science-health/alzheimers-protein-loss-ease/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #kyotouniversity #alzheimer039s #brain #health

‘Birds Of A Feather’ Star Pauline Quirke Reveals Dementia Diagnosis
#News #Alzheimer039s #BirdsofaFeather #PaulineQuirke

https://deadline.com/2025/01/pauline-quirke-birds-of-a-feather-dementia-diagnosis-1236262126/

‘Duck Dynasty’s Phil Robertson Diagnosed With Alzheimer’s Disease
#News #Alzheimer039s #DuckDynasty #Health #PhilRobertson

https://deadline.com/2024/12/duck-dynasty-phil-robertson-diagnosed-alzheimers-disease-1236196863/

Japanese researchers have developed a technique to identify individuals who may have Alzheimer’s disease by asking simple questions and observing their behavior. https://www.japantimes.co.jp/news/2024/11/28/japan/science-health/keio-university-alzheimers/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #keiouniversity #medicine

The European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval of sales of lecanemab to treat Alzheimer's disease. https://www.japantimes.co.jp/news/2024/11/15/japan/science-health/lecanemab-drug-switch-recommendation/ #japan #sciencehealth #lecanemab #alzheimer039s #pharmaceuticals #nationalhealthcare #dementia #medicine #health

Japan's Central Social Insurance Medical Council, which advises the health minister, approved public health insurance coverage for donanemab, an Alzheimer's medicine developed by U.S. drugmaker Eli Lilly. https://www.japantimes.co.jp/news/2024/11/13/japan/science-health/insuarance-coverage-alzheimers-drug/ #japan #sciencehealth #alzheimer039s #pharmaceuticals #donanemab #nationalhealthcare #mentalhealth #dementia #medicine

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain

Japan's health ministry is expected to soon approve new Alzheimer’s drug donanemab after a ministry panel backed the move. https://www.japantimes.co.jp/news/2024/08/02/japan/science-health/alzheimers-donanemab-approval-expected/ #japan #sciencehealth #elililly #alzheimer039s #pharmaceuticals #health #mentalhealth #dementia #medicine #donanemab

Scientists have made another major stride toward the long-sought goal of diagnosing Alzheimer’s disease with a simple blood test. https://www.japantimes.co.jp/news/2024/07/29/world/science-health/blood-test-alzheimer-study/ #worldnews #sciencehealth #dementia #alzheimer039s #genetics #aging #elderly

Worryingly for Japan and its rapidly aging population, new findings highlight the effects of heat on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. https://www.japantimes.co.jp/news/2024/07/29/japan/science-health/extreme-heat-dementia-japan/ #japan #sciencehealth #heat #heatwaves #climatechange #dementia #health #alzheimer039s #aging #elderly #brain

Europe's medicines watchdog has rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits. https://www.japantimes.co.jp/news/2024/07/27/japan/science-health/europe-watchdog-alzheimers-drug/ #japan #sciencehealth #eisai #alzheimer039s #aging #health #dementia #medicine

A diabetes drug has been found to eliminate senescent cells — which accumulate with age and contribute to hardening of the arteries and other diseases — in mice, paving the way for research on aging-related diseases, researchers at a Tokyo university say. https://www.japantimes.co.jp/news/2024/05/31/japan/science-health/diabetes-drug-aging/ #japan #sciencehealth #dementia #aging #juntendouniversity #alzheimer039s #pharmaceuticals

Japanese researchers have confirmed a way to predict the onset of Alzheimer’s disease with a high degree of probability, by checking blood for the presence of a certain type of abnormal protein that causes the illness. https://www.japantimes.co.jp/news/2024/05/23/japan/science-health/japan-alzheimers-detection/ #japan #sciencehealth #universityoftokyo #alzheimer039s #dementia

Teams of researchers from Niigata University and the University of Tokyo have begun an international clinical trial to check the effectiveness and safety of a treatment for familial Alzheimer's disease. https://www.japantimes.co.jp/news/2024/03/15/japan/science-health/familial-alzheimers-treatment-trial/ #japan #sciencehealth #alzheimer039s #eisai #pharmaceuticals

Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, according to a company spokesperson. https://www.japantimes.co.jp/business/2024/02/05/companies/eisai-alzheimers-drug-china/?utm_content=buffer2498b&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #business #companies #eisai #pharmaceuticals #alzheimer039s #china

Maybe we won't live forever, but who says we can't live till at least 100 in good health? @Tomoko_Otake looks at efforts to stave off the ill effects of aging in Japan. https://www.japantimes.co.jp/news/2024/01/27/japan/science-health/science-immortality-aging-centenarians/?utm_content=buffer91f08&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #immortality #death #aging #health #elderly #alzheimer039s

New Alzheimer's drug lecanemab will cost around ¥2.98 million per year in Japan, but will be largely covered by public health insurance that will limit the burden for patients to between 10% and 30% of that cost, subject to a cap, a health ministry body has said. https://www.japantimes.co.jp/news/2023/12/13/japan/eisai-biogen-alzheimers-drug-price/?utm_content=buffer4dd52&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #alzheimer039s #drugs #eisai #biogen #pharmaceuticals

Day Service Happy in Kochi Prefecture is taking a different approach to dementia care in Japan by encouraging paid volunteer work and social integration. https://www.japantimes.co.jp/news/2023/08/22/japan/science-health/dementia-care-facility/?utm_content=buffer03554&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #alzheimer039s #health #mentalhealth #dementia #kochi

A health ministry panel reviewing the new Alzheimer’s drug lecanemab greenlighted its approval in Japan on Monday. https://www.japantimes.co.jp/news/2023/08/21/japan/science-health/lecanemab-alzheimers-drug-approval/?utm_content=buffer356e4&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #lecanemab #eisai #alzheimer039s #pharmaceuticals #health